for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jaguar Health Inc

JAGX.OQ

Latest Trade

1.44USD

Change

0.03(+2.13%)

Volume

97,416

Today's Range

1.32

 - 

1.45

52 Week Range

1.01

 - 

175.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.41
Open
1.38
Volume
97,416
3M AVG Volume
20.38
Today's High
1.45
Today's Low
1.32
52 Week High
175.00
52 Week Low
1.01
Shares Out (MIL)
41.25
Market Cap (MIL)
8.60
Forward P/E
-0.24
Dividend (Yield %)
--

Latest Developments

More

Jaguar Health Inc Files For Offering Of 1.8 Mln Class A Units

Jaguar Health Inc Files Preliminary Prospectus Related To Offering 3.5 Million Class A Units

Jaguar Health Inc Selling Stockholders Are Offering On Resale Basis From Time To Time Aggregate Of Up To 13,782 Shares Of Voting Common Stock Of Co

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Jaguar Health Inc

Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

Industry

Biotechnology & Drugs

Contact Info

201 Mission St Ste 2375

+1.415.8965081

https://jaguar.health/

Executive Leadership

James J. Bochnowski

Independent Chairman of the Board

Lisa A. Conte

President, Chief Executive Officer, Director

Steven R. King

Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary

Carol R. Lizak

Chief Accounting Officer

Jonathan Wolin

Chief of Staff and General Counsel

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1,417.500

2019(E)

-5.900
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.65
Price To Book (MRQ)
8.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
78.56
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-122.38
Return on Equity (TTM)
-76.44

Latest News

BRIEF-Jaguar Health Files For Resale Of Up To 29.4 Mln Shares Common Stock By The Selling Shareholders

* JAGUAR HEALTH INC FILES FOR RESALE OF UP TO 29.4 MILLION SHARES COMMON STOCK BY THE SELLING SHAREHOLDERS - SEC FILING Source : https://bit.ly/2qOl6Fa Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Jaguar Health Says Unit Signed Agreement With ADAP Crisis Task Force

* JAGUAR INC SAYS NAPO PHARMACEUTICALS HAS SIGNED AN AGREEMENT WITH ADAP CRISIS TASK FORCE

BRIEF-Jaguar Health Inc Files For Non-Timely 10-K With U.S. SEC

* JAGUAR HEALTH INC FILES FOR NON-TIMELY 10-K WITH U.S. SEC Source text: (https://bit.ly/2GQ2TRx) Further company coverage:

BRIEF-Jaguar Health Says Entered Securities Purchase Agreement With Chicago Venture Partners - SEC Filing​

* JAGUAR HEALTH - ON FEB 26, CO ENTERED SECURITIES PURCHASE AGREEMENT WITH CHICAGO VENTURE PARTNERS - SEC FILING

BRIEF-Jaguar Health Says Unit Napo Pharmaceuticals Signs Deal With Transition Patient Services To Establish Nationwide Pilot "Mytesi Direct" Program

* JAGUAR HEALTH - UNIT NAPO PHARMACEUTICALS SIGNS DEAL WITH TRANSITION PATIENT SERVICES TO ESTABLISH NATIONWIDE PILOT “MYTESI DIRECT” PROGRAM

BRIEF-Jaguar Health Files For Resale Or Other Disposition Of Up To 6.02 Mln Shares Of Voting Common Stock

* JAGUAR HEALTH INC FILES FOR RESALE OR OTHER DISPOSITION OF UP TO 6.02 MILLION SHARES OF VOTING COMMON STOCK - SEC FILING Source text: [http://bit.ly/2BJoioW] Further company coverage:

BRIEF-Jaguar Health Provides Updates Regarding Programs

* JAGUAR HEALTH PROVIDES UPDATES REGARDING COMMERCIAL, EDUCATIONAL & PRODUCT DEVELOPMENT PROGRAMS AND 2017 RESULTS FOR MYTESI SINCE MERGER (AUGUST–DECEMBER 2017) Source text for Eikon: Further company coverage:

BRIEF-Jaguar Health Says Unit Entered Amendment To Note Purchase Agreement

* JAGUAR HEALTH - ON DEC 29, 2017, UNIT ENTERED AMENDMENT TO NOTE PURCHASE AGREEMENT & NOTES WITH EACH OF PURCHASERS PARTY TO AGREEMENT DATED MARCH 1, 2017

BRIEF-Jaguar Health ‍Enters Collaboration Agreement With SEED For Equilevia​

* JAGUAR HEALTH INC - ENTERED COLLABORATION AGREEMENT WITH SEED MENA BUSINESSMEN SERVICES FOR EQUILEVIA

BRIEF-Jaguar Health enters share purchase agreement

* JAGUAR HEALTH ENTERS SHARE PURCHASE AGREEMENT FOR 2 MILLION SHARES AND COMMON STOCK PURCHASE AGREEMENT RELATING TO A 10 MILLION SHARE EQUITY LINE OFFERING WITH L2 CAPITAL, LLC

BRIEF-Jaguar Health ‍signs non-binding term sheet to issue note to Iliad Research

* Jaguar health enters non-binding agreement of terms to issue a secured convertible note to iliad research and trading, l.p. (an affiliate of chicago venture partners, l.p.), as jaguar expands commercial efforts for mytesi

BRIEF-Jaguar Health enters into letter agreement with Maxim Group LLC

* Jaguar Health - on Oct 25,co entered into letter agreement with Maxim Group LLC which amends certain terms of underwriting agreement dated Sept 29 Source text : (http://bit.ly/2y8b9cc) Further company coverage:

BRIEF-Jaguar Health files for resale or other disposition of up to 36 million shares of co

* Jaguar Health files for resale or other disposition of up to 36 million shares of co by the selling shareholders Source text: (http://bit.ly/2gxkRxa) Further company coverage:

BRIEF-Jaguar Health prices $4.25 million public offering of common stock

* Jaguar health prices $4.25 million public offering of common stock

BRIEF-Jaguar unit Napo Pharmaceuticals files CMC supplement with FDA

* Jaguar subsidiary Napo Pharmaceuticals files CMC supplement with FDA for sample-size bottles of mytesi, Napo's FDA-approved human drug, to support upcoming national sample campaign Source text for Eikon: Further company coverage:

BRIEF-Jaguar Health says FDA indicates co's Canalevia drug qualifies as “minor use” for exercise-induced diarrhea in dogs

* FDA indicates that jaguar’s Canalevia drug product candidate qualifies as “minor use” for Exercise-Induced Diarrhea (EID) in dogs, rendering Canalevia eligible for conditional approval for this indication

BRIEF-Jaguar Health proposes public offering of common stock

* Jaguar Health announces proposed public offering of common stock

BRIEF-Jaguar Health subsidiary expands Mytesi salesforce

* Jaguar Health subsidiary Napo Pharmaceuticals expands Mytesi salesforce with hire of experienced HIV & GI drug sales reps in key U.S. markets Source text for Eikon: Further company coverage:

BRIEF-Jaguar Health files for mixed shelf of up to $60 mln

* Jaguar Health Inc files for mixed shelf of up to $60 million - sec filing

BRIEF-Nantucket Investments Limited reports 19.9 pct passive stake in Jaguar Health as of July 31 - SEC Filing

* Nantucket Investments Limited reports 19.9 percent passive stake in Jaguar health Inc as of July 31 - SEC Filing Source text: (http://bit.ly/2uq1H1V) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up